Skip to content

Blood-Based Biomarkers study in traumatic brain injury

Blood-Based Biomarkers study in traumatic brain injury

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600129144
Enrollment
Unknown
Registered
2026-07-31
Start date
2024-04-12
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

traumatic brain injury

Interventions

traumatic brain injury :None
non-brain injury from trauma :None

Sponsors

The Army Specialized Medical Center of the People's Liberation Army of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Inclusion criteria for the TBI group: (1) Clinically diagnosed as traumatic brain injury based on medical history and imaging signs from the Trauma Biopsy Repository; (2) Age ranging from 18 to 80 years old. 2. Inclusion criteria for the non-brain injury from trauma group: (1) Age ranging from 18 to 80 years old; (2) Clinically diagnosed as trauma patients (except for brain trauma) based on medical history and imaging signs; (3) Visited the Department of War Trauma Medicine of our hospital within 24 hours after the injury; (4) The patient or their legal guardian voluntarily signed the informed consent form. 3. Inclusion criteria for the healthy control group: (1) Healthy individuals matched with the case group in terms of age and gender; (2) No previous history of neurological diseases (such as cerebral infarction, cerebral hemorrhage, cognitive impairment-related diseases); (3)Voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with previous neurological disorders (such as cerebral infarction, cerebral hemorrhage, and diseases related to cognitive impairment); 2. Severe coronary heart disease, heart dysfunction, atrial fibrillation and other heart diseases; severe liver and kidney dysfunction; severe blood system diseases, coagulation disorders; advanced malignant tumors, etc.; 3.Those who violated the research rules, had poor compliance or refused to participate in this project.

Design outcomes

Primary

MeasureTime frame
Diagnostic and predictive performance: area under the curve (AUC), accuracy, sensitivity, specificity;

Secondary

MeasureTime frame
neurofilament light chain;total tau;glial fibrillary acidic protein;ubiquitin carboxyl-terminal hydrolase L1;

Countries

China

Contacts

Public ContactYanjiang Wang

The Army Specialized Medical Center of the People's Liberation Army of China

wayaja@163.com+86 23 6875 7851

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026